Stockwinners Market Radar for November 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EST Harbour BioMed, Moderna enter into collaboration agreement - Harbour BioMed "announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX a global biotechnology company pioneering messenger RNA therapeutics and vaccines. The strategic collaboration will focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using the Company's proprietary heavy chain only antibody discovery platform. Upon the execution of the agreement and subject to terms and conditions thereof, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the Company's HCAb platform, to develop products using nucleic acids. Moderna will assume full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities. Moderna would also be granted an option to obtain an exclusive sub-licensable license to exploit sequences against additional targets. Pursuant to the agreement, Nona Biosciences shall receive an upfront payment, and potential milestone payments based on pending achievement of certain regulatory, development, and sales milestones, and tiered royalties."

18:58 EST Marathon Oil exec Henderson sells 80,000 common shares - In a regulatory filing, Marathon Oil executive VP of operations Michael Henderson disclosed the sale of 80,000 common shares of the company on November 8 at a price of $32.5556 per share.

17:44 EST FTC restores rigorous enforcement of law banning unfair methods of competition - The Federal Trade Commission issued a statement that restores the agency's policy of rigorously enforcing the federal ban on unfair methods of competition. Congress gave the FTC the unique authority to identify and police against these practices, beyond what the other antitrust statutes cover. But in recent years the agency has not always carried out that responsibility consistently. The FTC's previous policy restricted its oversight to a narrower set of circumstances, making it harder for the agency to challenge the full array of anticompetitive behavior in the market. Today's statement removes this restriction and declares the agency's intent to exercise its full statutory authority against companies that use unfair tactics to gain an advantage instead of competing on the merits. "When Congress created the FTC, it clearly commanded us to crack down on unfair methods of competition," said FTC Chair Lina M. Khan. "Enforcers have to use discretion, but that doesn't give us the right to ignore a central part of our mandate. Today's policy statement reactivates Section 5 and puts us on track to faithfully enforce the law as Congress designed." Companies that may be impacted include Meta Platforms (META), Alphabet (GOOG) and Apple (AAPL). Reference Link

17:37 EST AIG announces five-year employment agreement with CEO Peter Zaffino - American International Group announced that AIG and Peter Zaffino, President & CEO and Chairman of the Board, have entered into an agreement securing Zaffino's employment through November 10, 2027.

17:31 EST CVD Equipment gets $3.7M aerospace order for coating system - The company states: "CVD Equipment announced that it has received an order for a Production Chemical Vapor Infiltration (CVI) System valued at approximately $3.7M. The system will be used to manufacture Ceramic Composite Materials (CMCs) for Aerospace Gas Turbine Engines. CVD is a leading manufacturer of Chemical Vapor Infiltration and Tow-Coating Systems for use in the aerospace industry. Although gas turbine engine production was greatly impacted due to the COVID-19 pandemic and the resulting decline in long haul travel, the aerospace industry is showing signs of recovery, although we do not expect a recovery to pre-pandemic levels until later in 2023. The increased demand for fuel-efficient/fuel-economy aircraft is driving development of next generation engine platforms that are energy efficient with reduced weight and reduced operating emissions. Advanced materials such as CMCs, enable increased fuel efficiency, along with higher strength and 1/3rd the weight compared to conventional nickel-based superalloys."

17:28 EST Google expands its user choice billing pilot - Paul Feng, VP, Product Management said in part on Google's Android Developers Blog: "Building on Android's long history of continuously evolving to provide users and developers more flexibility and choice, we announced earlier this year that we would begin exploring expanded billing options on Google Play (GOOG, GOOGL)) through our user choice billing pilot..Pilot participants can offer an additional billing system alongside Google Play's billing system for their users in select countries...When we announced the pilot, we noted that we were starting with Spotify (SPOT) as our very first partner. We've been working closely with the Spotify team and are excited to announce that this week they begin rolling out an initial test implementation of user choice billing to their users in select countries. We expect the experience will likely evolve over time as they continue to iterate and learn. Spotify has announced more detail on this rollout here. We're also excited that Bumble (BMBL) has joined to partner with us in our user choice billing pilot. We're working with their teams and we anticipate their users will begin seeing this choice in-app in select countries in the coming months. Additionally, with strong interest from developers around the world, in September we opened participation in the pilot to to all developers of non-gaming apps... we are excited to announce that based on the positive response and initial feedback from developers and users, we are expanding the pilot to users in the United States, Brazil, and South Africa." Reference Link

17:14 EST SP Plus acquires assets of India-based DIVRT - SP Plus has acquired certain assets of DIVRT, a developer of software and technology solutions that enable frictionless parking capabilities. SP+ has acquired all the intellectual property of DIVRT and a team of over 20 technology engineers based in India.

17:05 EST Middleby acquires Escher Mixers, terms not disclosed - Middleby announced the acquisition of Escher Mixers, a designer and manufacturer of highly-engineered spiral and planetary mixers for the industrial baking industry. Escher customers include large grocery and retail chains, and they provide established solutions for the artisanal bread and pastry industries. Located in Vicenza, Italy, the company has annual revenues of $15M.

17:01 EST Marriott raises quarterly dividend 33% to 40c per share - Marriott International announced that its board of directors declared a quarterly cash dividend of 40c per share of common stock, which represents a 33% increase over the previous quarterly dividend amount of 30c per share and reflects the company's earnings growth and strong cash generation. The dividend is payable on December 30, 2022, to shareholders of record as of the close of business on November 23, 2022. The company also announced that its board has increased the authorization to repurchase the company's Class A common stock by an additional 25M shares, for a total of approximately 30.8M shares currently authorized for repurchase. Year-to-date through November 9, 2022, the company has repurchased 11.6M shares for $1.8B.

16:42 EST Bowman Consulting sees initial FY23 net service billings $270M-$290M - Sees initial FY23 adjusted EBITDA at $42M-$48M.

16:41 EST Ultragenyx announces departure of CFO Dier - Ultragenyx Pharmaceutical announced that Mardi Dier, Chief Financial Officer, CFO, and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN. Ted Huizenga, Chief Accounting Officer, and Aaron Olsen, Senior Vice President of Corporate Strategy and Finance, will lead ongoing finance activities during the search for a successor.

16:37 EST Alkaline Water now projects $20M in total cost savings, margin enhancements - The Alkaline Water Company Inc. provided an update on its Pathway to Profitability, announcing another $5M in potential costs savings and margin enhancements. Total estimated savings, once fully implemented throughout fiscal years 2023 and 2024, are now approximately $20M compared to fiscal year 2022. This morning, the company also announced that it expects to report record revenue of approximately $19.6M when it files its 10-Q for its second quarter fiscal 2023 next Monday, November 14th, 2022, after market close. "The Alkaline Water Company continues to find ways to be more efficient while maintaining strong sales momentum in pursuit of our ultimate goal of becoming a profitable company," stated Frank Lazaran, President and CEO of The Alkaline Water Company. "We have now identified approximately $20 million in total savings and margin improvement compared to last fiscal year. Though it will take time to see the full benefits of the measures we're taking to improve our bottom line, we look forward to sharing with our shareholders next week the early progress we've made in our first full quarter on our Pathway to Profitability."

16:35 EST Northern Oil and Gas increases borrowing base to $1.6B from $1.3B - Northern Oil and Gas "announced the completion of its semi-annual borrowing base redetermination under its reserves-based revolving credit facility. The borrowing base under the facility was increased from $1.3 billion to $1.6 billion, and NOG has chosen to increase the elected commitment amount from $850.0 million to $1.0 billion."

16:34 EST OncoCyte has engaged advisor to assist in evaluating alternatives - The company said: "Looking ahead, we remain on track to submit our dossier for DetermaIO reimbursement in coming weeks. Additionally, our corporate development activities are yielding several interesting opportunities, and we have engaged Perella Weinburg Partners as our advisor to assist us in identifying and evaluating a range of potential strategic alternatives.On a parallel path, we continue to explore avenues to bolster our cash runway and to reduce our spend. We believe that Oncocyte has a bright future in front of us as the product development efforts from the past few years transition to market launches of several new high-value, reimbursed tests over coming quarters."

16:32 EST Steel Dynamics announces additional $1.5B share repurchase program - Steel Dynamics announced that the company's board of directors authorized an additional share repurchase program of up to $1.5B of the company's common stock. The authorization is effective immediately and is additive to the previous $1.25B program, which had $245M remaining authorized and available for repurchase on September 30.

16:29 EST Snail announces $5M share repurchase program - Snail, which came public earlier today, announced that its board of directors has authorized a share repurchase program under which Snail may repurchase up to $5M in outstanding shares of its Class A common stock, subject to ongoing compliance with Nasdaq listing rules.

16:18 EST Assurant raises quarterly dividend 3% to 70c per share - Assurant announced that its Board of Directors approved a quarterly dividend increase of 2c to 70c per share of common stock. The dividend will be payable on December 19, 2022 to stockholders of record as of the close of business on November 28, 2022. "We have a compelling strategy with strong business fundamentals, and we continue to be good stewards of our capital," said Keith Demmings, President and CEO, Assurant. "Our ability to increase our dividend for the 18th consecutive time since our initial public offering is a testament to the strength of our ongoing and future cash generation."

16:17 EST Momentus chief revenue officer Harms to retire - Momentus announced that Dawn Harms, Chief Revenue Officer, will retire effective Dec. 31, 2022. "We express our heartfelt thanks to Dawn for her leadership, resilience, and dedication to our company and our customers," said Momentus Chief Executive Officer John Rood. "Dawn's contributions were integral to the transformation of our Company, particularly as we started trading on the NASDAQ last August, and as we flew our first demonstration mission in May 2022. On behalf of the entire team, we wish Dawn the best in her well-earned retirement." Harms joined Momentus in 2019 as Chief Revenue Officer, leading the Company's commercial sales strategy. Momentus plans to announce a successor to Harms later this year.

16:09 EST National Storage appoints Fischer to Executive Chair, Cramer to CEO - National Storage Affiliates Trust announced its Board of Trustees has elevated Tamara Fischer, Chief Executive Officer, CEO, to Executive Chair, effective April 1, 2023. Tammy has served as an officer of NSA since its IPO in 2015 and as its CEO and member of the Board of Trustees of NSA since 2020. As part of this planned transition of responsibilities, effective April 1, 2023, David Cramer will be appointed Chief Executive Officer, in addition to his current role as President. Arlen Nordhagen will remain on the Board and will transition to Vice Chair, from his current role as Executive Chairman. The Board further announced the appointment of Derek Bergeon to Executive Vice President and Chief Operating Officer effective April 1, 2023. Derek joined NSA in 2019 and currently serves as Senior Vice President, Operations.

16:02 EST Integral Ad Science names CFO, effective December 5 - Integral Ad Science announced the appointment of Tania Secor as CFO, effective December 5, 2022. Secor will lead the global finance team and report directly to Lisa Utzschneider, CEO of IAS. Most recently, she served as Global CFO of R/GA and Reprise, Interpublic Group's digital innovation and digital media agencies, respectively.

15:26 EST GM, Sempra's SDG&E to explore vehicle-to-grid and vehicle-to-home technology - San Diego Gas & Electric (SRE) and General Motors (GM) announced an agreement to investigate the feasibility of integrating bidirectional Electric Vehicles into the electric grid as a local energy resource. Following GM's announcement of its newest business unit, GM Energy, the study will examine the hardware, software, processes and construction considerations necessary to accelerate wider adoption of Vehicle-to-Grid Integration capabilities, the companies said. Reference Link

15:18 EST GT Biopharma CEO says 'pleased with progress' with TriKE platform - GT Biopharma announced it will present two poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting, or SITC 2022, to be held in Boston, Massachusetts and virtually on November 8-12. The two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer. "We are pleased with the progress that has been made in assessing the broad applicability of our novel TriKE platform across solid tumors" said Michael Breen, Executive Chairman and Interim CEO of GT Biopharma. "Our TriKE structure consisting of an anti-CD16 nanobody which binds to NK cells and triggers antibody directed cell-mediated cytotoxicity, IL-15 cross-linker that binds to NK cells inducing self-sustaining expansion and extended survival and an anti-tumor associated antigen which binds to well-known tumor antigens. The TriKE modular platform allows for targeting multiple tumor-associated antigens. As such, we remain excited in our progress to date while looking forward to submitting an Investigational New Drug application in 2023 for lead assets GTB-3650 targeting CD33 positive tumors and GTB-5550 targeting B7H3 positive tumors, respectively."

14:50 EST Lottery.com names Matthew Howard McGahan chairman - Lottery.com announced the appointment of an existing director, Matthew Howard McGahan as Chairman of the Board. This announcement comes at a transformational time for the company. The company has also appointment two new Board members; Barney Battles and Naila Chowdhury. These appointments fill two recent vacancies on the company's Board. The company looks forward to benefiting from Barney's significant professional accountancy related expertise and Naila's experience in building global business partnerships.

14:50 EST California AG sues DuPont, 3M over 'toxic forever chemicals' - California Attorney General Rob Bonta has filed a lawsuit against the manufacturers of per- and polyfluoroalkyl substances, commonly referred to as PFAS, for "endangering public health, causing irreparable harm to the state's natural resources, and engaging in a widespread campaign to deceive the public." In the lawsuit, Attorney General Bonta alleges that these manufacturers, including 3M and DuPont, knew or should have known that PFAS are toxic and harmful to human health and the environment, yet continued to produce them for mass use and concealed their harms from the public. As a result, these toxic "forever chemicals" are pervasive across California's bays, lakes, streams, and rivers; in its fish, wildlife, and soil; and in the bloodstream of 98% of Californians. "PFAS are as ubiquitous in California as they are harmful," said Attorney General Bonta. "As a result of a decades-long campaign of deception, PFAS are in our waters, our clothing, our houses, and even our bodies. The damage caused by 3M [MMM], DuPont [DD], and other manufacturers of PFAS is nothing short of staggering, and without drastic action, California will be dealing with the harms of these toxic chemicals for generations. Today's lawsuit is the result of a years-long investigation that found that the manufacturers of PFAS knowingly violated state consumer protection and environmental laws. We won't let them off the hook for the pernicious damage done to our state." In the lawsuit, Attorney General Bonta alleges that the manufacturers knew or should have known about the dangers of PFAS when they made and/or sold products containing them and that the manufacturers' failed to warn about the dangers of PFAS and in many cases concealed them. The lawsuit seeks injunctive relief, damages, penalties, restitution, and abatement. Requested relief includes statewide treatment and destruction of PFAS, including, but not limited to, the treatment of drinking water by regulated water systems; water drawn from private wells and unregulated systems used for drinking water and irrigation; and water from other wastewater treatment plants and systems. The lawsuit also seeks payment of funds necessary to mitigate the impacts to human health and the environment through environmental testing, medical monitoring, public noticing, replacement water (for period between testing and installation of treatment), and safe disposal and destruction.

14:36 EST AMD calls new EPYC processors 'world's fastest and most energy efficient' - AMD has announced the general availability of the 4th Gen AMD EPYC processors with "unmatched performance for critical workloads across cloud, enterprise and high performance computing." The company stated: The 4th Gen AMD EPYC processors bring next-generation architecture, technology, and features to the modern data center. Built on the 'Zen 4' core, the highest performance core ever from AMDiv, the processors deliver leadership performance, energy efficiency and help customers accelerate data center modernization for greater application throughput and more actionable insights." Reference Link

14:32 EST Micron says DDR5 memory now available for 4th Gen AMD EPYC processors - Micron Technology (MU) announced availability of DDR5 memory for the data center that is validated for the new AMD EPYC 9004 Series processors. "The combination of 4th Gen AMD EPYC processors and Micron DDR5 delivers up to two times memory bandwidth on the STREAM benchmark and up to two times performance improvement on select HPC workloads such as computational fluid dynamics, Weather Research and Forecasting modeling and CP2K molecular dynamics," the company stated.

14:17 EST Senator Rubio, Representative Gallagher call for national TikTok ban - U.S. Senator Marco Rubio and U.S. Representative Mike Gallagher announced that they are introducing legislation which would ban TikTok and "other social media companies that are effectively controlled by the CCP" from operating in the United States. Companies that compete with TikTok for advertising dollars include Meta Platforms' (META) Facebook and Instagram, Alphabet's (GOOGL) Google and YouTube and Snap's (SNAP) Snapchat. Reference Link

13:37 EST FTX US says trading may be halted 'in a few days' - FTX US posted the following announcement at the top of its site: "trading may be halted on FTX US in a few days. Please close down any positions you want to close down. Withdrawals are and will remain open. We will give updates as we have them." Reference Link

13:29 EST Vickers Vantage Corp I trading halted, volatility trading pause

13:06 EST NYSE to suspend trading immediately in Cohn Robbins, start delisting proceedings - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist three securities of Cohn Robbins Holdings Corp. from the NYSE, including the Class A ordinary shares. Trading in the company's securities will be suspended immediately. The NYSE will apply to the Securities and Exchange Commission to delist the company's securities upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision.

13:00 EST Silo Pharma CEO says 'everything fully staffed' as COVID reopening continues

12:48 EST Roper Technologies raises dividend 10% to 68.25c per share - Roper Technologies announced that its board of directors has declared a quarterly cash dividend of 68.25c per share, payable on January 23, 2023 to stockholders of record as of January 9, 2023. This represents an increase of 10% over the dividend paid in each quarter of 2022, or an expected 25c increase on an annual basis, or 6.25c on a quarterly basis, Roper noted.

12:30 EST Enovix names Ajay Marathe COO - Enovix announced the appointment of Ajay Marathe as COO reporting to CEO Harold Rust. Marathe's 38-year career includes stints as COO, CIO and foreign-subsidiary CEO of major technology companies including Western Digital Corporation, Lumileds LLC and Advanced Micro Devices, where he served for 23 years first as Thailand Plant Manager responsible for assembly and test of six million units per week, and then VP of Operations of the 2,500-employee Computation Products group, and then VP of Operations for all Asian assembly and test, and finally CEO of the AMD India LLC startup created to serve the entire country. Enovix CEO, Harold Rust said, "We wanted to find a senior semiconductor executive who thinks 'millions not thousands' and scored with Ajay, a known Silicon Valley industry figure."

12:02 EST Twitter CISO Lea Kissner departs - In a Thursday tweet, Twitter's chief information security officer Lea Kissner said, "I've made the hard decision to leave Twitter. I've had the opportunity to work with amazing people and I'm so proud of the privacy, security, and IT teams and the work we've done. I'm looking forward to figuring out what's next, starting with my reviews for @USENIXSecurity". Reference Link

12:00 EST Small Cap Bear 3x falls -17.7% - Small Cap Bear 3x is down -17.7%, or -$6.52 to $30.42.

12:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -24.1% - Direxion Daily Semiconductor Bear 3X Shares is down -24.1%, or -$13.17 to $41.44.

12:00 EST Wayfair rises 32.9% - Wayfair is up 32.9%, or $9.47 to $38.22.

11:50 EST Ibex Ltd trading resumes

11:45 EST Ibex Ltd trading halted, volatility trading pause

11:34 EST LiveOne board authorizes $2M increase to stock repurchase program - LiveOne announced that its board of directors has authorized it to expand its previously announced stock repurchase program by up to an additional $2,000,000 worth of shares of its common stock to be repurchased from time to time. Since April 1, 2022, LiveOne has repurchased 2,000,000 shares under the program. The authorization to repurchase will expire on December 31, 2023.

11:21 EST AGBA Acquisition Ltd trading resumes

11:16 EST AGBA Acquisition Ltd trading halted, volatility trading pause

11:06 EST Iqvia, Clalit Health Services partner to advance research in Israel - IQVIA announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country. The collaboration combines IQVIA and Clalit's capabilities in clinical trial delivery, real-world research, data and genomics. Clalit operates a network of 14 hospitals and over 1600 primary care clinics. The health services organization provides full therapeutic coverage with significant expertise in, but not limited to, oncology, pediatric rare disease, and genomics. With this combined expertise, the collaboration will allow for focus on the future of innovation, including precision medicine and the delivery of data driven trials.

10:45 EST Vigil Neuroscience Inc trading resumes

10:41 EST Sanofi, GSK's VidPrevtyn Beta approved by European Commission - After the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older. Designed to provide broad protection against multiple variants, the protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK's pandemic adjuvant. VidPrevtyn Beta is indicated as a booster for active immunization against SARS_CoV_2 in adults who have previously received an mRNA or adenoviral COVID vaccine. Shipments of VidPrevtyn Beta are ready to be distributed to European countries as per Advance Purchase Agreements.

10:36 EST ASML announces share buyback program of up to EUR 12B - ASML said it expects to continue to return significant amounts of cash to shareholders through a combination of growing dividends and share buybacks. ASML announced a new share buyback program, effective today and to be executed by December 31, 2025. It intends to repurchase shares up to an amount of EUR 12.0B, of which it expects a total of up to 2M shares will be used to cover employee share plans.

10:12 EST Huadi International Group Co trading resumes

10:05 EST Huadi International Group Co trading halted, volatility trading pause

10:00 EST Azul falls -15.2% - Azul is down -15.2%, or -$1.33 to $7.47.

10:00 EST Web Street, Inc. falls -18.2% - Web Street, Inc. is down -18.2%, or -$9.33 to $41.80.

10:00 EST RingCentral rises 23.0% - RingCentral is up 23.0%, or $6.51 to $34.87.

09:54 EST Asante Gold says Bibiani ramp up remains on track - Asante Gold announced that the Bibiani Gold Mine ramp up remains on track and commercial production has been established with three months of consistent production since the first gold pour was completed in early July 2022. Operational highlights include: The first gold pour at Bibiani was completed July 7, 2022, two months ahead of schedule. Metallurgical performance and gold production is on track with the ramp up schedule. All process plant and mine facilities have been operating on a 24 hour per day basis from late June, with ~220,000 tonnes in September and~206,000 tonnes in October. Asante plans to increase throughput to 250,000 tonnes ore per month by Q1 2023. Gold production in September was above 9,300 ounces, 17% above the Company's start up plan. October production was 9,910 ounces, 15% above plan. Gold production will continue to ramp up to ~20,000 oz per month by early 2023. The Walsh Pit continues to outperform relative to our initial planned gold production. As this pit has been developed, the grade control drilling program has been a key component to development of this trend. The Company's plan to extend the Bibiani open pit Life of Mine from 8.3 years to +10 years is on track with successful development exploration at Russel South and drilling programs continue at the Grasshopper and Elizabeth deposits as planned. The Company will continue its near mine development exploration program with planned drilling of approximately 30,000 metres per year for 2022, 2023 and 2024. The Bibiani orebodies typically dip near-vertical and are open at depth. Bibiani has initiated an underground mine planning study to define development of an underground mine operation that will access mineralized deposits below the Main Pit and the satellite pits. Asante anticipates the underground mine program initiative will increase annual gold production significantly and proceed from 2025 and extend mine life beyond the period of open pit mining.

09:51 EST Motorsport Games completes 1-for-10 reverse stock split - Motorsport Games confirmed that the 1-for-10 reverse stock split of the Company's Class A and Class B common stock became effective as of 12:01 a.m. EST on November 10, 2022. Motorsport Games effected the reverse stock split by filing a charter amendment with the Delaware Secretary of State. The reverse stock split was previously approved by the Company's Board of Directors and stockholders pursuant to Sections 228 and 242 of the Delaware General Corporation Law. The Company's Class A common stock began trading on the NASDAQ on a split-adjusted basis when the market opened today, November 10, 2022, under a new CUSIP number, 62011B 201. As a result of the reverse stock split, each 10 shares of the Company's Class A and Class B common stock issued and outstanding immediately prior to the Effective Time were automatically combined into 1 share of Class A common stock and Class B common stock, respectively, subject to the elimination of fractional shares, as described below. The same 1-for-10 reverse stock split ratio was used to effect the reverse stock split of both Motorsport Games Class A and Class B common stock, and accordingly, all stockholders were affected proportionately. The reverse stock split reduced the Company's issued and outstanding shares of common stock from approximately 11,673,587 shares of Class A common stock and 7,000,000 shares of Class B common stock to approximately 1,167,358 and 700,000 shares, respectively. The number of shares of Class A common stock subject to the Company's outstanding employee and director stock options, as well as the relevant exercise price per share, will be proportionately adjusted to reflect the reverse stock split. Accordingly, the approximately 821,962 outstanding stock options will be reduced to approximately 82,196 outstanding stock options. The number of shares authorized for issuance under the Company's stock plan will also be reduced from 1,000,000 shares of Class A common stock to 100,000 shares of Class A common stock using the same 1-for-10 split ratio. The Company has notified NASDAQ that the Company is not in compliance with the Nasdaq Listing Rules requiring minimum of 500,000 publicly held shares.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares falls -16.6% - Direxion Daily Semiconductor Bear 3X Shares is down -16.6%, or -$9.04 to $45.57.

09:47 EST Local Bounti rises 21.0% - Local Bounti is up 21.0%, or 53c to $3.05.

09:47 EST Yeti rises 21.6% - Yeti is up 21.6%, or $6.56 to $36.90.

09:42 EST WidePoint says PKI technology delivers on CISA guidance - WidePoint Corporation announced that the company's Public Key Infrastructure Identity & Access Management solution delivers on new guidance issued by CISA, the Cybersecurity & Infrastructure Security Agency of the U.S. Department of Homeland Security. CISA released two fact sheets to highlight threats against accounts and systems using certain forms of Multi-Factor Authentication. CISA urges all organizations to implement phishing-resistant MFA to protect against phishing and other known cyber threats. Public Key Infrastructure is at the top of the phishing-resistant MFA technologies.

09:40 EST Sealed Air invests $9M in solar farm powering California manufacturing facility - Sealed Air has invested $9 million in a solar farm that is now powering its Madera, California manufacturing facility. The solar panels, which sit on 11 acres of company-owned land adjacent to the facility, are expected to help reduce energy spend at this site by $1 million annually. The 265,000 square foot plant, which manufactures BUBBLE WRAP brand original cushioning, SEALED AIR brand Korrvu retention and suspension packaging, mailers, and other solutions, will have 98% of its electricity powered by the solar field.

09:36 EST Brightline Interactive to power technology demonstration with AT&T - Brightline Interactive is powering and connecting its immersive technologies in collaboration with AT&T for an integrated technological demonstration at the I/ITSEC, the largest training and simulation tradeshow in the United States. This will be the first instance where two fully rollable NOVA simulator domes and an additional mixed reality user are connected via AT&T's 5G network, driving super-fast data throughput, leading to minimal delay in visual presentation, thereby enabling complex and realistic multi-user training in a fully immersive environment. AT&T has integrated a temporary 5G network inside of Brightline's immersive laboratory for application testing, staging, and metrics capture in preparation for the I/ITSEC tradeshow.

09:34 EST Live Current Media completes acquisition of assets of PowerSpike - Live Current Media completed the acquisition of the assets of PowerSpike, including all code to PowerSpike's powerful influencer management software and all social media sites supporting the product. The all-stock transaction was concluded on November 9th, 2022. The PowerSpike product is a comprehensive and extendable influencer management software platform that includes scalable data tracking and analysis tools, client facing reporting and monitoring applications with real-time chat processing and inference tools. More significantly, the tech stack has the ability to screen and source millions of social media handles, filtering for subject matters, number of followers, and other key characteristics. More than seventy thousand creators have already signed up to use PowerStrike and the assets include a list of another ten million influencers in numerous niches. Capitalizing on a growing demand for acquiring and analyzing data, the Company plans to expand and to monetize the new platform features by integrating and rolling out this unique platform across all other products within the Company's product portfolio and ecosystem.

09:32 EST Ralph Lauren sees gross margin expansion in 2H

09:32 EST Ralph Lauren sees FY23 gross margin up 30-50bps

09:31 EST AMV Stock trading halted, volatility trading pause

09:30 EST American Resources' ReElement secures manufacturing readiness grant - American Resources Corporation announced that it has been awarded a $200,000, state-level, advanced manufacturing grant from the Indiana Economic Development Corporation for its patented critical battery element purification and separation technology being commercialized in Noblesville, Indiana.

09:28 EST Adagene announces clinical data at SITC 2022 on ADG116 - Adagene announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer's, SITC, Annual Meeting taking place in Boston. Key findings as of the data cutoff date on September 19, 2022 include: Compelling, differentiated safety profile demonstrated with ADG116 monotherapy up to 15 mg/kg: ADG116 is well tolerated across dose levels with repeat dosing. Grade 1/2 and Grade 3/4 treatment-related adverse events were reported in 28 and 3 patients, respectively. With repeat dosing and tracking for late-onset toxicities in the same 10mg/kg cohort, the overall rate of Grade 3 or higher TRAEs is 13%. For reference, the reported rate of TRAEs Grade 3 and higher for the currently approved anti-CTLA-4 therapy, ipilimumab, is approximately 36% at 10 mg/kg in first-line monotherapy in melanoma patients. There were no Grade 3 or higher TRAEs reported at the 15 mg/kg dose level for ADG116 monotherapy. Combination dosing optimization advances: Although ADG116 with toripalimab at 6 mg/kg did not meet the target toxicity level, 3 mg/kg of ADG116 every three weeks with toripalimab was both manageable within the TTL and demonstrated impressive efficacy in difficult-to-treat tumors. Further dose optimization is planned, including ongoing evaluation of an extended dosing interval of ADG116 every six weeks plus toripalimab to meet the desired TTL. Potential combination efficacy demonstrated in cold tumors, and an intriguing case study of a confirmed, durable complete response in head and neck cancer. Findings from a second poster, "A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody(TM) ADG116 in Combination with Pembrolizumab in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update", established a safe and potentially active dose level for ADG116 in combination with pembrolizumab. Data evaluating ADG116 in combination with pembrolizumab in six heavily pre-treated patients primarily with cold tumors further support the differentiated safety profile of ADG116 dosed at 3 mg/kg every three weeks, and its efficacy potential when combined with pembrolizumab at a flat dose of 200 mg. No TRAEs higher than Grade 3 were reported and no DLT was observed.

09:25 EST Diana Shipping announces delivery of m/v DSI Polaris - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/v DSI Polaris, a 2018 built Ultramax dry bulk vessel of 60,404 dwt. The vessel is one of nine modern Ultramax dry bulk vessels that the Company entered into an agreement to purchase in August 2022.

09:25 EST Tivic Health announces manufacturing partnership with Microart Services - Tivic Health announced it has entered into an agreement with Microart Services, headquartered in Buffalo, New York, to manufacture, on a non-exclusive basis, certain components and sub-assemblies of the company's current and future products.

09:24 EST Allakos presents preclinical data on AK007 - Allakos announced a poster presentation at the Society for Immunotherapy of Cancer's, SITC, 37th Annual Meeting. The poster presentation highlights pre-clinical data supporting Siglec-10 as a promising myeloid target for enhancing anti-tumor immunity in solid tumors. SITC Poster Details: The poster titled "Antibody blockade of the immunoinhibitory receptor Siglec-10 polarizes tumor-associated myeloid cells and promotes anti-tumor immunity" will be presented on Friday, November 11th, key findings include: Siglec-10 is a myeloid inhibitory checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells. Siglec-10 expression is upregulated in multiple solid cancers and inversely correlates with patient survival in colon adenocarcinoma. Siglec-10 antagonist mAb monotherapy treatment inhibited tumor growth in a syngeneic colon adenocarcinoma model in Siglec-10 transgenic mice. Reduced tumor growth was associated with an expansion and activation of TAMs, dendritic cells, and T lymphocytes in the tumor, consistent with the mechanism of action.

09:23 EST Medicenna reports data from Phase 1/2 ABILITY study of MDNA11 - Medicenna Therapeutics announced new safety, pharmacokinetic, and pharmacodynamic data from the first four dose escalation cohorts of the Phase 1/2 ABILITY study of MDNA11, the Company's "beta-only" long-acting IL-2 super-agonist. The data are featured in two posters being presented at the Society for Immunotherapy of Cancer, or SITC, 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8-12. The ABILITY study is currently enrolling patients in its fifth dose-escalation cohort, two 30 microgram/kg "priming" doses of MDNA11 followed by fixed doses of 90 microgram/kg. Initial anti-tumor activity from the fifth dose escalation cohort, alongside a broader update from all of the trial's dose escalation cohorts, is expected in the first quarter of 2023. "The clinical data being presented at SITC are encouraging and reassert MDNA11's potential as a best-in-class IL-2 super-agonist by virtue of its desirable PK, PD, and safety features, along with the promising signs of anti-tumor activity it has displayed in heavily pre-treated, end-stage patients," said Fahar Merchant, PhD, President and CEO of Medicenna. "We were particularly pleased to see MDNA11's PK profile remaining consistent with repeat dosing, which suggests the absence of an anti-drug antibody response. Moreover, we have continued to see MDNA11 selectively and dose-dependently stimulating anti-cancer immune cells through ABILITY's low and mid-dose cohorts, suggesting potential for further increases in anti-tumor activity as we enroll patients in higher dose cohorts that employ the optimized dosing schedule that will be implemented in the trial's dose expansion phase."

09:22 EST Tingo Mobile launches operations in Ghana - Tingo opened a head office in Accra, Ghana and has launched nationwide operations. Tingo Mobile's business in Ghana is held through a wholly owned subsidiary, Tingo Mobile Ghana. Ghana is regarded as a hugely important market for Tingo Mobile and its Pan-African expansion strategy, not least because of its strong and well-developed agricultural sector, as well as its considerable and thriving export market in non-staple products. Tingo Mobile has committed to work closely with the Ghanaian Government and its Ministry of Food and Agriculture to achieve its goal of growing Ghana's agriculture sector's contribution towards Gross Domestic Product, to be in excess of 25% by 2025, compared to 19.1% in 2020, including through the improvement of crop production efficiency and crop yield, as well as the reduction of post-harvest losses. To coincide with its launch, Tingo Ghana has agreed on a landmark trade deal with the Kingdom of Ashanti, through the Ashanti Kingdom Investment Trust. The Kingdom of Ashanti presides over Ghana's Ashanti Region, which has a population of approximately 5.4 million, and through its dominant position in Ghana and Ghana's agricultural sector, also has a degree of influence over much of the country's population of 32 million. Under the terms of the trade deal, the Ashanti Kingdom Investment Trust has committed to enroll a minimum of 2 million new members with Tingo within 120 days of signing and has agreed on a target to increase such enrollments to at least 4 million members. Tingo Mobile is replicating in Ghana the same proven business model that has generated more than $526 million of revenues and $298 million of net income before tax in Nigeria in the first half of 2022. In addition to rolling out its Nwassa Agri-Fintech marketplace platform in Ghana, Tingo Mobile is also plans to launch the TingoPay SuperApp in the coming weeks, to include payment services, in partnership with Visa.

09:21 EST BriaCell reports breast cancer efficacy data with Bria-IMT treatment - BriaCell Therapeutics announces positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT in combination with Incyte's retifanlimab. Title: An off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors: In summary, the findings show evidence of clinical and survival benefits in heavily pre-treated advanced breast cancer patients, suggesting an additive or synergistic effect of Bria-IMT in combination with PD-1 inhibitors, and supporting the strategy of using the Bria-IMT combination regimen with retifanlimab for the treatment of advanced breast cancer patients. Overall, the company is very impressed by the clinical data of the combination study to date and look forward to sharing additional data at the upcoming SABCS conference in December. Title: Evidence of immune system activation by Bria-OTS+ and Bria-PROS. Both Bria-OTS+ for advanced breast cancer, and Bria-PROS(TM) for advanced prostate cancer, were able to activate naive T cells, suggesting their potential capabilities to produce very strong immune responses in patients. Results show that the very strong immune responses observed may be due to: direct activation of the components of the immune system such as naive T cells, and indirect activation of the immune system components via production of immune activating molecules.

09:20 EST Nurix Therapeutics reports completion of DeTIL-0255 Phase 1 safety run-in - Nurix Therapeutics presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 - 12th in Boston. Nurix also announced the successful completion of the safety run-in portion of the ongoing Phase 1 trial of DeTIL-0255 in patients with advanced gynecologic malignancies and revealed that it has received feedback from the FDA regarding the potential combination of DeTIL-0255 with the oral CBL-B inhibitor NX-1607. The FDA feedback, the preliminary safety profile of DeTIL-0255, and the potential benefits of combining DeTIL-0255 with in vivo pharmacologic inhibition of CBL-B with NX-1607 provide a path for a potential future combination trial to explore whether inhibiting CBL-B both ex vivo and in vivo may enhance the anti-tumor potential of adoptive cell therapy. "We believe that our portfolio of first-in-class CBL-B inhibitors has the potential to improve outcomes for patients with solid tumors and enhance the field of cell therapy," said Robert J. Brown, M.D., executive vice president of clinical development at Nurix. "Pending successful completion of Nurix's NX-1607 Phase 1a dose escalation trial, we envision expanding the use of NX-1607 as a single agent in selected indications in 2023. We also can see a path to exploring the potential for a combination strategy with DeTIL-0255 in accordance with recent feedback from the FDA." The Phase 1 safety run-in includes three patients with advanced epithelial ovarian cancer who have been dosed with DeTIL-0255 and have cleared the initial safety evaluation. Expansion of the Phase 1 trial will be postponed, pending potential inclusion of NX-1607 in future cohorts.

09:19 EST Nurix Therapeutics announces initial Phase 1 NX-1607 data presented at SITC - Nurix Therapeutics presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607. These data are being presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 - 12th in Boston. Nurix has identified and characterized novel proximal biomarkers including phosphorylated hematopoietic lineage cell-specific protein 1 whose levels increase when CBL-B is inhibited and can be measured in ex vivo stimulated whole blood in animals and humans indicating the ability of these cells to become activated in the presence of an antigen signal such as those found in the tumor microenvironment. pHS1 is an important downstream signal of T cell activation. Preliminary pharmacokinetics and pharmacodynamic measurement of pHS1 were used to characterize the activity of NX-1607 in a first-in-human clinical trial. These data demonstrate dose-responsive target engagement as measured by increases in biomarker levels in stimulated human whole blood with NX-1607 treatment reaching levels associated with anti-tumor activity in animal models at dose level 1 and increasing at higher doses. Preliminary PK data suggest NX-1607 has dose-proportional exposures and a mean half-life of 6 to 8 hours at doses ranging from 5 mg to 50 mg.

09:18 EST Cue Biopharma reports new data from ongoing Phase 1 trial of CUE-101 combo - Cue Biopharma (CEU) announced the presentation of new "positive data" from its ongoing Phase 1 trial evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101 in combination with pembrolizumab, or Keytruda (MRK), as a first line therapy for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma, or HNSCC. The data will be presented in a poster at the Society for Immunotherapy of Cancer's 37th Annual Meeting, or SITC 2022, to be held in Boston, Massachusetts and virtually on November 8-12. The poster will also provide an update from the company's ongoing fully enrolled Phase 1b trial evaluating CUE-101 monotherapy as third line and beyond therapy in the same patient population. Additionally, the company will present two posters discussing the design of its ongoing Phase 1 trial evaluating its second IL-2 based candidate, CUE-102, for the treatment of Wilms' Tumor 1 positive malignancies, and preclinical data regarding its mechanistic effect in vitro and in vivo. "We are very encouraged with the overall response rate observed in the trial so far with CUE-101, and its potential to improve standard of care for HPV+ head and neck cancer patients," said Dr. Christine Chung, M.D., Chair, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, and a principal investigator participating in the clinical trial. "There is an urgent need for more effective and durable treatment options with less side effects as more than half of all patients with recurrent/metastatic HNSCC given the current standard of care will experience disease progression. I look forward to following this promising CUE-101 clinical data through."

09:17 EST Tempest Therapeutics presents data on TPST-1120 - Tempest Therapeutics announced the presentation of data on TPST-1120, an oral selective peroxisome-proliferator activated receptor-alpha antagonist, and TPST-1495, a dual antagonist of both EP2 and EP4 prostaglandin receptors, at the Society for Immunotherapy of Cancer 37th Annual Meeting taking place November 10-12, 2022 in Boston, MA. The biomarker results presented from the TPST-1120 Phase 1 clinical study demonstrate pharmacodynamic changes in circulating blood in patients who received clinical benefit from therapy that are consistent with blocking the activity of PPAR-alpha. In addition, data presented from TPST-1495 showed that its dual antagonism of EP2 and EP4 generated significantly greater immune activation in human immune cells and anticancer activity in mouse tumor models than single inhibitors of either receptor, or the COX-2 inhibitor, celecoxib. TPST-1120: "Pharmacodynamic and Predictive Biomarkers Associated with Response in Cancer Patients Treated with TPST-1120: a First-in-class, Small Molecule Antagonist of Peroxisome-Proliferator Activated Receptor-Alpha"" In a late-breaking poster presentation, data from a Phase 1 trial with monotherapy and nivolumab combination arms were used to assess gene expression changes in post-treatment whole blood from 30 patients and to perform baseline mutational analysis on ctDNA to identify potential biomarkers. The data showed that seven genes were modulated by TPST-1120 exposure, including genes associated with enhanced immune responsiveness, stimulation of monocytes or macrophages and PPAR-alpha blockade. The results were consistent across monotherapy and combination arms. Patients in the combination arm who had a partial response to treatment had significant elevations in multiple genes, including those associated with Th17 development, lipid transport and down-regulation of CD155, a TIGIT ligand. Mutational analysis revealed that patients with a PR or stable disease were more likely to bear mutations in isocitrate dehydrogenase and phosphatase and tensin homolog compared to patients with progressive disease. TPST-1495: "Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway" In a second presentation, the data demonstrated that TPST-1495 was more effective than EP2 and EP4 single antagonists, and the COX-2 antagonist, celecoxib, in mouse and human whole blood assays. TPST-1495 conferred a near complete restoration of immune function in cellular assays, even in the presence of high PGE2 concentrations. In lung carcinoma tumors and in a spontaneous tumor mouse model of CRC, TPST-1495 decreased tumor size and number of tumors. Immunohistochemistry analysis of the resected small intestine tumors revealed increased immune infiltrate and an enhanced adaptive immune transcriptional profile.

09:15 EST Portage Biotech presents updated data on Phase 1/2 trial on PORT-2 - Portage Biotech announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with non-small cell lung cancer and advanced melanoma, at the Society for Immunotherapy of Cancer's 37th Annual Meeting. "We are encouraged by the growing patient data set that supports the preliminary Phase 1 results showing that PORT-2 has a favorable safety and tolerability profile as a monotherapy at all doses tested to date," said Dr. Ian Walters, Chief Executive Officer of Portage Biotech. "We continue to see single agent activity of PORT-2 at the 3 mg/m2 dose, which is the mid-dose level in our study. Based on the results so far, we are confident in the mechanistic potential of PORT-2 to activate both the adaptive and innate immune system and reduce the suppressive cells in the tumor microenvironment." Dr. Walters continued, "Furthermore, in these patient populations that have failed multiple previous lines of treatment, it is essential that we provide new therapeutic options that could be administered as a monotherapy or complement other approaches. Having recently announced our clinical collaboration with Merck, we are pleased to have begun treating patients with PORT-2 in combination with pembrolizumab. PORT-2 has been shown to increase PD-L1 expression and thus has the potential for synergistic combination with checkpoint inhibitors and for the expansion of the use of anti-PD-1 therapy to an entirely new group of patients who do not currently respond to treatment. Interestingly, we observed a dose dependent increase in CD86+ B cells (which function as antigen presenting cells) in the blood of patients following PORT-2, which has been associated with response to checkpoint inhibitors. We look forward to sharing further updates from the current study as well as progress in our randomized clinical trial evaluating PORT-2 as a monotherapy and in combination with pembrolizumab in the coming year."

09:13 EST Biodesix presents new data from INSIGHT study at SITC - Biodesix announced that Wallace Akerley, MD, medical oncologist at the University of Utah Huntsman Cancer Institute, will present new interim data from the large multi-center prospective observational registry study INSIGHT at the Society for Immunotherapy of Cancer, SITC, 37th Annual Meeting. The data highlights the ability of the VeriStrat test, a novel predictive and prognostic blood-based host immune classifier, to stratify immune checkpoint inhibition treatment response in patients with advanced non-small cell lung cancer, NSCLC. The poster, titled "Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results from the INSIGHT Registry Study," will be presented on Friday, November 11. Results from a prior analysis of the VeriStrat test published in the Journal for ImmunoTherapy of Cancer in October 2021 demonstrated that approximately 2,000 patients with at least one year of follow up classified by VeriStrat as host immune classifier hot (HIC-Hot) had better outcomes, on average living 2-3 times longer when compared to patients classified by VeriStrat as host immune classifier cold. A classification of HIC-H, also known as VeriStrat Good, implies that the normal tumor directed immunity is active and patients are potentially responsive to therapies that boost immune response. HIC-C classification, also known as VeriStrat Poor, correlates to what experts refer to as an "immune desert," where tumor directed immunity is compromised.

09:12 EST Zealand Pharma expects revenue from license agreements in 2022 - The company will no longer provide guidance on net product revenue, reflecting the completion of the asset purchase agreement for V-Go with MannKind Corporation and the completion of the global license and development agreement for Zegalogue with Novo Nordisk. In 2022, Zealand expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand does not intend to provide guidance on such revenue. Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%*. This is unchanged from our updated guidance issued on March 30, 2022.

09:10 EST Sensei Biotherapeutics presents preclinical data at SITC for SNS-101 - Sensei Biotherapeutics presented preclinical data for SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei's discovery-stage SNS-102 program, at the Society for Immunotherapy of Cancer, SITC, 37th Annual Meeting. Poster presentation titled, "SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8 T-cells" Summary: SNS-101 did not bind to human or non-human primates VISTA+ monocytes, neutrophils and natural killer cells in blood or other normal tissue compartments. SNS-101 induced significant expansion of naive CD8 T-cells and memory CD4 and CD8 T-cells in vivo without activation or depletion of monocytes. SNS-101 exhibited linear elimination kinetics in non-human primates, overcoming TMDD-induced pharmacokinetic limitations observed with other anti-VISTA antibodies. IND filing for SNS-101 is anticipated in the first half of 2023. Poster presentation titled, "Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4." Highlights: Development of multiple functional assays demonstrated VSIG4-mediated suppression of primary human CD4 T-cells. Through the LRC-TriCEPS proteomics screen, a set of potentially novel T cell receptor candidates that interact with VSIG4 were identified. A Cas9/CRISPR-based target gene knockdown methodology will be implemented for validation of VSIG4-interacting T-cell receptor candidates. An initial set of pH-selective anti-VSIG4 antibodies have been identified and further optimization is ongoing to identify a lead antibody.

09:09 EST Nektar's NKTR-288 shows enhanced anti-tumor activity in - Nektar (NJTR) announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer Annual Meeting. NKTR-288 is a novel polyethylene glycol-conjugate of interferon gamma designed to modify binding of IFN-gamma to its substrates and optimize the duration of IFN-gamma signaling. IFN-gamma is a cytokine that induces cellular antigen presentation and enhances tumor antigen-specific cytotoxic T cell response, and may have applications in a number of therapeutic areas, including oncology and infectious diseases, among others. The presentation showed the sustained pharmacological properties of NKTR-288 relative to native cytokine, including durable exposure and induction of the well characterized interferon gamma response. These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting. Also presented at SITC by Nektar's partner, Merck (MRK), is a trials in progress poster of the Phase 2 JAVELIN Bladder Medley study. The ongoing clinical trial includes evaluation of Bavenio - avelumab -, Merck's anti-PD-L1 therapy, in combination with NKTR-255, Nektar's IL-15 receptor agonist designed to increase the proliferation and survival of natural killer cells and memory CD8+ T cells to enhance anti-tumor immunity. Merck KGaA is running this study and is on track to generate comparative progression-free survival data for this study by the end of 2024.

09:07 EST Gritstone announces overall survival results from GRANITE Phase 1/2 study - Gritstone bio announced updated overall survival results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy, for the treatment of advanced solid tumors. These results, along with results from a clinicopathologic analysis of metastatic MSS-CRC patients with and without a molecular response, will be presented via a poster at the Society for Immunotherapy of Cancer 37th Annual Meeting. The Phase 1/2 study is evaluating the safety, immunogenicity, and clinical activity of GRANITE in combination with PD-1 checkpoint inhibitor, nivolumab and subcutaneous anti-CTLA-4 antibody ipilimumab in advanced solid tumors. This study enrolled and treated 29 patients with previously treated, metastatic solid tumors including patients with colorectal cancer, gastroesophageal adenocarcinoma, and non-small cell lung cancer. Of 13 patients with MSS-CRC, 6 experienced a molecular response defined as greater than or equal to30% reduction in circulating tumor DNA and continue to have an overall survival advantage compared to those patients without a molecular response.Updated OS data from GRANITE Phase 1/2: 6 of 13 treated patients with MSS-CRC had a molecular response and the observed median overall survival in this group will now exceed 22 months. This compares to a median overall survival not yet reached and exceeding 18 months as reported in May 2022. Clinicopathologic characteristics from GRANITE Phase 1/2: 4 of 6 patients with molecular response had liver metastasis. All patients had PD-L1 expression less than1% and low levels of IFNg-related gene expression. Median tumor mutational burden was 2.9 and 3.6 mutations/MB in those with and without molecular response, respectively.

09:07 EST Choice Hotels signs agreement with Noble Investment Group - Choice Hotels signed an agreement with Noble Investment Group to develop nine WoodSpring Suites hotels in Georgia and South Carolina over the next two years, signaling increased institutional interest in the largest economy extended-stay brand in the market.

09:06 EST Tingo Mobile launches operations in Ghana - MICT, Inc. (MICT) and Tingo, Inc. (TMNA), announced that Tingo Mobile, which is being wholly acquired by MICT with a scheduled completion date of November 30, 2022, has today opened a head office in Accra, Ghana and has launched nationwide operations. Tingo Mobile's business in Ghana is held through a wholly owned subsidiary, Tingo Mobile Ghana. Ghana is regarded as a hugely important market for Tingo Mobile and its Pan-African expansion strategy, not least because of its strong and well-developed agricultural sector, as well as its considerable and thriving export market in non-staple products. Tingo Mobile has committed to work closely with the Ghanaian Government and its Ministry of Food and Agriculture to achieve its goal of growing Ghana's agriculture sector's contribution towards Gross Domestic Product, to be in excess of 25% by 2025 compared to 19.1% in 2020, including through the improvement of crop production efficiency and crop yield, as well as the reduction of post-harvest losses. To coincide with its launch, Tingo Ghana has agreed on a landmark trade deal with the Kingdom of Ashanti, through the Ashanti Investment Trust. The Kingdom of Ashanti presides over Ghana's Ashanti Region, which has a population of approximately 5.4 million, and through its dominant position in Ghana and Ghana's agricultural sector, also has a degree of influence over much of the country's population of 32 million. Under the terms of the trade deal, the Ashanti Investment Trust has committed to enroll a minimum of 2 million new members with Tingo within 120 days of signing and has agreed on a target to increase such enrollments to at least 4 million members. Tingo Mobile is replicating in Ghana the same proven business model that has generated more than $526 million of revenues and $298 million of net income before tax in Nigeria in the first half of 2022. In addition to rolling out its Nwassa Agri-Fintech marketplace platform in Ghana, Tingo Mobile also plans to launch the TingoPay SuperApp in the coming weeks, to include payment services, in partnership with Visa. The Nwassa platform is expected to benefit from significant revenues on both the buy-side and sell-side in Ghana where, because of more developed agricultural practices, farmers have a greater demand for inputs, including equipment, fertilizers, and pesticides, for example. Such market conditions in Ghana are expected to lead to a higher level of Average Revenue Per User, which in turn is expected to lead to a further increase in profitability in 2023 and beyond.

09:05 EST B&G Foods cuts quarterly dividend to 19c from 47.5c per share - Along with its Q3 earnings announcement yesterday, B&G Foods also declared a reduced quarterly cash dividend of $0.19 per share of common stock. The dividend is payable on January 30, 2023 to stockholders of record as of December 30, 2022.

09:02 EST Jerash Holdings enters MOU for JV with Busana Apparel Group - Jerash also announced that on November 9, 2022, it signed a memorandum of understanding to establish a joint venture company with Busana Apparel Group to produce garments for Busana's retail customers that are expressing interest to geographically diversify and add production in Jordan, which has long-standing duty-free export agreements with the U.S., the EU and other countries.

09:00 EST BrainStorm trading resumes

08:57 EST ASP Isotopes announces pricing of IPO, Nasdaq listing - ASP Isotopes announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. In addition, ASPI has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The shares are expected to begin trading on the Nasdaq Capital Market LLC on November 10, 2022, under the ticker symbol "ASPI" and the offering is expected to close on or about November 14, 2022, subject to satisfaction of customary closing conditions. Revere Securities LLC is acting as sole book-running manager for the offering.

08:52 EST Blue Water expects cash to fund operations through end of Q3 of 2024 - Cash was $29.1 million as of September 30, 2022, as compared to $1.9 million as of December 31, 2021. The increase was primarily due to the closing of BWV's initial public offering in February 2022, a private placement that closed on April 19, 2022, and a private placement that closed on August 11, 2022. The Company believes its cash and cash equivalents are sufficient to fund operations through at least through the end of Q3 2024.

08:48 EST Cohn Robbins Holdings trading halted, news pending

08:47 EST American Resources announces $200K state-level grant from Indiana - American Resources announced that it has been awarded a $200,000, state-level, advanced manufacturing grant from the Indiana Economic Development Corporation for its patented critical battery element purification and separation technology being commercialized in Noblesville, Indiana.

08:46 EST Sellas Life Sciences announces data from its Phase 1/2 trial of galinpepimut-S - SELLAS Life Sciences Group (SLS) announced confirmatory top-line clinical data from the final analysis of results from its Phase 1/2 clinical trial of galinpepimut-S, the Company's Wilms Tumor-1-targeting peptide immunotherapeutic, in combination with Merck's anti-PD-1 therapy, pembrolizumab, in patients diagnosed with WT1 relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. Data from 17 patients enrolled in the study, conducted under a Clinical Trial Collaboration and Supply Agreement with Merck (MRK), have undergone final analysis for safety and efficacy. All enrolled patients were resistant to standard of care platinum-based therapy and 76.5 percent of the patients were refractory to or had failed their first- or second-line therapies. Summary of Top-Line Overall Survival and Progression-Free Survival Data: Median Overall Survival was 18.4 months compared to 13.8 months in a checkpoint inhibitor single agent study in a similar patient population treated with checkpoint inhibitor alone; Median Progression-Free Survival was 12 weeks compared to eight weeks in a checkpoint inhibitor single agent study in a similar patient population treated with checkpoint inhibitor alone; The overall response rate of the trial is 6.3 percent with a disease control rate (DCR), which is the sum of overall response rate and rate of stable disease, of 50.1 percent at a median follow-up of 14.4 months. In a checkpoint inhibitor single agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2 percent, consistent with a DCR rate increase of approximately 45 percent in the GPS combination with Keytruda over that seen for checkpoint inhibitors alone. Importantly, survival and disease control benefits were observed in patients harboring tumors with any level of detectable PD-L1 expression, i.e., those with Combined Positive Score, CPS, of one or higher. In the Phase 1/2 study, patients with a CPS score of less than one showed a median OS of 3.2 months vs. patients with a CPS greater than or equal to one who had a median OS of 18.4 months and, as it relates to time to progression, patients with a CPS score of less than one had a median PFS of 1.9 months and patients with a CPS score of greater than or equal than one showed a median PFS of 3.8 months. The safety profile of GPS in combination with pembrolizumab was similar to pembrolizumab alone, with the only addition of low-grade, rapidly resolving local reactions at the GPS injection site, consistent with observations from other GPS clinical studies.

08:44 EST Tryp Therapeutics announces poster presentations at SfN Conference - Tryp Therapeutics announced that the Company's collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience Conference, to be held from November 12-16, 2022 in San Diego. Details of the poster presentations are as follows: Title: Psilocybin Attenuates Mechanical Allodynia and Thermal Hyperalgesia in a Rodent Model of Formalin-Induced Chronic Pain: The study results demonstrated that a single intravenous dose of psilocybin can attenuate mechanical allodynia and thermal hyperalgesia for up to 4 weeks post dose. Title: Intravenous Psilocybin Alters Brain Network Dynamics in Rats: This study demonstrated a change in EEG recordings in rats receiving an IV infusion of psilocybin coincident with achieving the psychedelic state. Jim Gilligan, Chief Executive Officer, stated, "We are excited our collaborators at the University of Michigan are presenting the results of our two recent studies. The first study explored intravenous psilocybin and its effect in a recognized rat model of fibromyalgia. This model exhibits increased sensitivity to touch and hypersensitivity to elevated temperatures. Administration of a single intravenous infusion of psilocybin resulted in a decrease in both pain and heat sensitivity persisting until the end of the study. Tryp is the first company to pursue the use of psychedelics in nociplastic pain indications including fibromyalgia. These results support the potential clinical utility of psilocybin assisted therapy in the treatment of patients with fibromyalgia. The second study demonstrated a change in EEG recordings coincident with achieving the psychedelic state. Rats received a continuous intravenous infusion of psilocybin over a period of 60 minutes while EEG data were simultaneously monitored. The results demonstrate the ability to detect changes in EEG patterns coincident with attaining the psychedelic state. In addition, upon cessation of the infusion a return to baseline EEG patterns correlated with decreasing blood levels of psilocin. This study will help facilitate Tryp's program to utilize EEG recordings to optimize dose and infusion rates of TRP-8803 in planned upcoming clinical trials."

08:43 EST Recon Technology regains compliance with Nasdaq minimum bid price requirement - Recon Technology received notification from Nasdaq confirming the company has cured the bid price deficiency, and that the Company is in compliance with all applicable listing standards. The company's stock will continue to be listed and traded on The Nasdaq Stock Market.

08:42 EST Imunon enters into technology evaluation agreement with Acuitas Therapeutics - IMUNON and Acuitas Therapeutics announced the signing of an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models. "We are delighted to enter into this technology evaluation agreement with Acuitas Therapeutics, an organization renowned for its delivery technology capabilities, particularly with its LNP systems for mRNA vaccines," said Corinne Le Goff, Ph.D., President and Chief Executive Officer of IMUNON. "In light of the recent successes with our PLACCINE technology and promising proof-of-concept SARS CoV-2 data in non-human primates, we believe the time is right to explore the expansion of our technology to other types of delivery systems as we position our nucleic acid-based modality as the future of vaccinology."

08:41 EST 3D Systems, ALM announce partnership to expand access to 3D printing materials - 3D Systems and ALM announced they have entered into a partnership to expand access to industry-leading 3D printing materials. ALM will add 3D Systems' DuraForm PAx material to its portfolio, providing its customers access to a unique copolymer specifically designed for use with available Selective Laser Sintering, SLS, technologies. As a result, ALM's customers will have access to an expanded materials portfolio enabling them to choose the best material for their application. "We're excited to announce this collaboration with ALM, not only to expand access to this game-changing copolymer but to also show what's possible when two industry leaders work towards a shared goal," said Dr. David Leigh, EVP and chief technology officer for additive manufacturing, 3D Systems. "By joining together, 3D Systems and ALM are not only helping manufacturers innovate more rapidly, but we're also able to redirect our innovation pipelines to create more first-to-market materials. I believe this in turn will also foster future 3D printing technology innovations thus creating additional options for manufacturers to procure the optimal solution for their application."

08:40 EST Ballard Power and Fusion Fuel commission H2Evora green hydrogen plant - Ballard Power (BLDP) and Fusion Fuel (HTOO) completed the interconnection of Fusion Fuel's H2Evora plant to the Portuguese electric grid and successfully commissioned the facility. The demonstration project, comprised of 15 HEVO-Solar units and associated balance of plant equipment, will produce 15 tons of green hydrogen per year and avoid the emission of 135 tons of CO2 annually. The facility includes a 200-kilowatt FCwaveTM fuel cell module supplied by Ballard Power, which is used to convert its green hydrogen into electricity. The integration of Fusion Fuel's solar-to-hydrogen HEVO solution and Ballard's fuel cell technology is a proof of concept for the use of hydrogen as a flexible energy storage vector and off-grid power supply.

08:39 EST Inspira Technologies granted patent by Israeli Patent Office - Inspira Technologies announced that the Israeli Patent Office granted a patent for a key safety component of the INSPIRA ART system. The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.

08:37 EST Viatris wins court decision invalidating AstraZeneca's Symbicort patent - Viatris (VTRS), a global healthcare company announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's (AZN) Symbicort patent, U.S. Patent No. 10,166,247, is invalid. The district court determined that the patent is invalid on two separate grounds - lack of written description and lack of enablement. Viatris President Rajiv Malik said: "We are extremely pleased with the court's decision as it clears away yet another of AstraZeneca's invalid patents, which have only served to block generic versions and delay access to this important product for American patients. This affirms Viatris' continuing efforts to break down barriers to patient access for important medicines. We already have FDA approval for our generic Symbicort product, and we look forward to the opportunity to bring our more affordable product to market."

08:36 EST U.S. Gold sells interest in Maggie Creek Property for $2.75M - U.S. Gold (USAU) announced the execution on November 9 of a transaction related to the Maggie Creek Property among Nevada Gold Mines, Orogen Royalties, and U.S. Gold. Renaissance Exploration, a wholly-owned subsidiary of Orogen, and the company's wholly-owned subsidiary, Orevada Metals, are parties to an Exploration Earn-In Agreement pursuant to which Orevada, by making certain payments and incurring certain exploration expenditures, has the right to earn at least a 50% interest and up to a 70% interest in the Maggie Creek Property, owned by RenEx, in Eureka County, Nevada. U.S. Gold caused Orevada to assign its interest in the Original Earn-In Agreement to NGM. Simultaneous with that assignment, NGM and RenEx entered into an agreement pursuant to which NGM can earn a 100% interest in the Maggie Creek Property. As consideration for the assignment of the Original Earn-In Agreement to NGM, U.S. Gold received an upfront cash payment of $2.75M dollars from NGM, and NGM agreed that if it exercises the NGM Option and acquires the Maggie Creek Property, it will grant to U.S. Gold a 0.5% Net Smelter Returns royalty on all gold and other recovered and saleable minerals from the Maggie Creek Property, pursuant to a separate royalty agreement between NGM and U.S. Gold. Under the U.S. Gold Royalty Agreement, NGM will have the right to buy back one-half of the U.S. Gold Royalty for a fixed price of $500K. In addition, the U.S. Gold Royalty Agreement will provide that U.S. Gold waives the first $800K of production royalty payments owed to it, regardless of whether NGM exercises its buy-back rights. Under the U.S. Gold Royalty Agreement, NGM will also have a right of first refusal to purchase the U.S. Gold Royalty if U.S. Gold decides to sell that royalty.

08:34 EST Stack Capital reports Q3 book value per share $11.75 - Book Value per Share of the Company was $11.75, as compared with $11.25 as at September 30, 2021, a 4% increase. The Company's cash position was $43.2 million, or $4.68 per share."We continue to diligently evaluate companies to add to our portfolio that we believe are market leaders with strong growth potential," said Jeff Parks, CEO of Stack Capital. "Given current market conditions, having 40% of our Book Value in cash is extremely beneficial and will enable us to opportunistically invest in attractive businesses that continue to grow in this economic environment. Scarcity of capital has resulted in better investment terms on recent deals that we have explored, with added benefits relating to downside protection. Overall, we remain excited for the future prospects of our existing portfolio companies."

08:31 EST Duke Energy to install microgrid at Marine Corps Base Camp Lejeune - Duke Energy has been awarded a $22M utility energy service contract by Marine Corps Base Camp Lejeune for the design and construction of a microgrid at the military base. The microgrid solution includes upgraded electrical infrastructure, 5 megawatts of on-site natural gas-fired generation, a 5.4-MW battery energy storage system, integration of an existing solar photovoltaic system, and a microgrid controller to provide integrated demand management, black start and islanding capability. Located in Onslow County, N.C., Camp Lejeune is home to the largest concentration of Marines in the Marine Corps.

08:29 EST BioCryst presents real-world data on the effects of ORLADEYO on HAE attacks - BioCryst Pharmaceuticals announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema, including patients who switched from other prophylactic therapies. The data are being presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, ACAAI. BioCryst ACAAI 2022 Presentation Highlights: Consistently Low Hereditary Angioedema Attack Rates Observed with Berotralstat Regardless of Previous Prophylaxis: This analysis assessed patient-reported HAE attack rates of patients on ORLADEYO 110 mg or 150 mg who were previously on another prophylactic therapy. Regardless of prior prophylaxis, a rapid reduction in median attack rates was observed early. The reduction of median attack rates was sustained throughout the 360-day treatment period. Upon initiating ORLADEYO treatment, the reduction in median attack rates from baseline over the 1-360 days period was consistent for patients regardless of their prior prophylaxis therapy. The reductions after starting ORLADEYO for each prior prophylactic therapy were: 77 percent reduction for patients previously on lanadelumab; 64 percent reduction for patients previously on SC C1-INH; 70 percent reduction for patients previously on danazol; and 72 percent reduction previously on IV C1-INH. The incidence of AEs reported was lower than the incidence reported in clinical trials. Rapid and Sustained Reductions in Hereditary Angioedema Attack Rates with Long-term Berotralstat: This analysis assessed the efficacy of ORLADEYO 110 mg or 150 mg in patients for a treatment period of more than 270 days. Patients reported a meaningful reduction in HAE attack rates when treated with ORLADEYO. An 80 percent average reduction from median baseline attack rate was observed during the initial 90-day treatment period.

08:25 EST Aileron Therapeutics announces 1-for-20 reverse stock split - Aileron Therapeutics announced that it will effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. ET today. Aileron's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "ALRN" and will begin trading on a split-adjusted basis when the market opens on November 11, 2022. The reverse stock split, which was approved by Aileron's stockholders on June 15, 2022, is intended to bring the company into compliance with Nasdaq's minimum bid price requirement. The new CUSIP number for the company's common stock following the reverse stock split will be 00887A 204.

08:25 EST BrainStorm trading halted, news pending

08:22 EST Establishment Labs announces Japan PMDA approval for Motiva Implants - Establishment Labs announced Motiva Implants and the Motiva Flora tissue expander have been approved for use in Japan by the Pharmaceuticals and Medical Devices Agency, or PMDA. The products have also received reimbursement for post-mastectomy reconstruction under the Japanese National Health System. The first reconstruction patient in Japan was successfully treated with Motiva in early November at Nagoya University Hospital.

08:21 EST TransUnion includes high-demand health audiences in TruAudience Data Marketplace - TransUnion announced the inclusion of high-demand health audiences from Veeva Crossix in its TruAudience Data Marketplace. Veeva Crossix is a top healthcare data provider and leader in health audience segments. The addition of this data will support more effective campaigns across streaming platforms.

08:19 EST Myriad Genetics announces launch of UroSuite - Myriad Genetics announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care. UroSuite includes Myriad's Prolaris Prostate Cancer Test, MyRisk Hereditary Cancer Test, BRACAnalysis CDx and Precise Tumor Molecular Profile Test. The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients. "Today's launch of UroSuite reinforces Myriad Genetics' commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists," said Paul J. Diaz, president and CEO, Myriad Genetics. "We continue to build on our efforts to elevate our products to their full potential and introduce new innovative solutions and analytics to help patients and healthcare providers with personalized genetic insights and data-driven medical information."

08:19 EST Enphase Energy expands IQ8 microinverter deployments in Oregon - Enphase Energy, announced that installers of Enphase products in Oregon have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters. "We are pleased to be working with Oregon's leading installers to meet the state's growing demand for solar," said Dave Ranhoff, chief commercial officer at Enphase Energy. "Together, we will continue to provide homeowners in Oregon with access to reliable energy solutions to keep their homes up and running even if the grid is down."

08:17 EST Genasys signs Zonehaven SaaS contract with Riverside County, California - Genasys announced a new multi-year software-as-a-service contract with Riverside County, California for Zonehaven evacuation resources.

08:17 EST Applied Molecular Transport announces FDA ODD granted to AMT-101 - Applied Molecular Transport announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT's proprietary carrier molecule, which is also in development for the treatment of ulcerative colitis and rheumatoid arthritis. "Pouchitis is a severe end-stage complication of ulcerative colitis with serious symptoms that have a tremendous negative impact on quality of life, including excessive stool frequency, urgency, fecal incontinence and chronic pain," said Bittoo Kanwar, M.D., chief medical officer of AMT. "Following the results observed in our FILLMORE trial demonstrating compelling activity of AMT-101 in pouchitis, we look forward to continued collaboration with the FDA as we remain focused on Phase 3 advancement in this patient population. If ultimately approved, AMT-101 may be the first product approved in the U.S. to treat pouchitis and potentially improve the lives of patients suffering from this condition."

08:13 EST Bionano Genomics appoints Donna Polizio as Global Head of Market Access - Bionano Genomics announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this new position, Ms. Polizio will be responsible for being the company's advocate with government and private payors to drive global reimbursement for OGM-based tests, with a strong focus on the US market. In addition, Ms. Polizio will lead Bionano's government relations efforts in connection with legislation that impacts Bionano, its products, and the genomics industry generally.

08:10 EST Benitec Biopharma reports Q1 EPS (47c) vs. (62c) last year - Reports Q1 revenue $0 vs. $0 last year."Following the receipt of a favorable decision from the Institutional Review Board of the lead clinical site for the OPMD Natural History Study in the United States and the formal completion of the Site Initiation Visit at this key clinical enrollment site, the screening of OPMD subjects for enrollment into the OPMD Natural History Study will begin this month. The initiation of subject screening for the OPMD Natural History Study represents a major milestone for Benitec, and we look forward to enrolling the first subjects into the OPMD Natural History Study this year. The enrollment of subjects into the OPMD Natural History Study in 2022 continues to support our central clinical development goal of administering the first dose of BB-301 in 2023," said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma. "The Principal Investigator of the OPMD Natural History Study in the United States expects high enrollment interest for this incurable genetic disease with no approved treatments, and we continue to work with regulators globally to open additional sites in geographies outside of the United States."

08:09 EST ViaSat and Cobham Satcom collaborate on maritime connectivity system - Viasat and Cobham Satcom, a global provider of satellite communications solutions to the maritime and land segments, are collaborating on a new, advanced satellite connectivity solution for the maritime and energy industries in preparation for the launch of Viasat's next generation satellite constellation, ViaSat-3. The connectivity system, which will include a portfolio of antenna systems from Cobham Satcom, is being designed to deliver high-speed connectivity that will leverage the satellite capacity expected from the ViaSat-3 constellation.

08:08 EST PepGen announces upcoming milestones - PGN-EDO51: PepGen anticipates initiating a Phase 2a multiple ascending dose (MAD) trial evaluating PGN-EDO51 in DMD patients in the first half of 2023. PGN-EDODM1: PepGen anticipates initiating a Phase 1/2 clinical trial in DM1 patients in the first half of 2023. PGN-EDO53: PepGen anticipates reporting NHP exon skipping data by the end of 2022 for PGN-EDO53, the Company's program for the treatment of DMD patients who are amenable to an exon 53 skipping approach. Additional Pipeline Assets: PepGen anticipates that it will nominate lead candidates for PGN-EDO45 and PGN-EDO44 by the end of 2022, which target DMD patient populations amenable to an exon 45 and exon 44 skipping approaches, respectively.

08:07 EST MeiraGTx expects cash to fund requirements into 4Q24 - In addition to the $25.0 million investment from JJDC, the Company had cash and cash equivalents of approximately $114.7 million as of September 30, 2022, as well as approximately $23.7 million in receivables due from Janssen from the third quarter of 2022. The Company believes it will have sufficient capital to fund operating expenses and capital expenditure requirements into the fourth quarter of 2024.

08:05 EST Axcelis announces multiple shipments of its Purion ion implanter systems - Axcelis announced multiple new and follow-on shipments of the Purion Power Series ion implanter systems. The shipments went to multiple fabs in Asia and Europe operated by leading Si and SiC power device chipmakers. These shipments include the first SiC tool shipped from the Axcelis Asia Operations Center in South Korea.

07:59 EST Yamana Gold announces new exploration drilling results across its assets - YAMANA GOLD announces new exploration drilling results across its asset portfolio, underscoring its strategic outlook and efforts to meaningfully extend and expand its sustainable production platform. Exploration results at Canadian Malartic, Wasamac and Jacobina support strong organic growth in mineral reserves, mineral resources and production through successful brownfield exploration programs. Further success at El Penon, Minera Florida and Cerro Moro is expected to significantly replace or reduce depletion due to mining, extending mine life, increasing sustainable production and enhancing asset value. The Company reports that the strong operational performance seen throughout the nine month period ended September 30 continued in the month of October.

07:55 EST Whitestone REIT releases 2022 ESG report - Whitestone REIT released its second Environmental, Social, and Governance, ESG, Report highlighting the Company's ESG strategic priorities and initiatives. Whitestone aligned its 2022 ESG Report with the Sustainability Accounting Standards Board industry standards and the Task Force on Climate-related Financial Disclosures recommendations. "We are proud to share Whitestone's second report on our environmental, social, and governance priorities and progress, demonstrating our commitments to our tenants, associates, and communities," says David Holeman, Chief Executive Officer. "We understand that managing our ESG responsibilities is critical to creating and sustaining long-term value."

07:53 EST AnPac Bio announces changes to board of directors - AnPac Bio-Medical Science announced the resignation of Yuyang Cui as the Co-Chair of the board of directors, and the Co-Chief Executive Officer, effective from November 7, 2022, and the resignation of Jiawen Kang from the position of a director of the Board, a member of the audit committee, and a member of the nominating and corporate governance committee, effective from November 4, 2022. Haohan Xu, the Co-Chairperson and Co-Chief Executive Officer of the Company, said, "On behalf of the Board of Directors and management team, I would like to express our sincere gratitude to them for all their contributions to the Company."

07:52 EST PyroGenesis announces conversion of methane into hydrogen production - PyroGenesis Canada announces that it has successfully produced hydrogen from methane using this revolutionary ZCE hydrogen production technology. PyroGenesis' plasma-based hydrogen production process converts this methane into a valuable solid carbon and hydrogen, thereby creating a ZCE hydrogen. The solid carbon is a byproduct that has many industrial applications, including the production of car tires, coatings, plastics, and batteries, and is considered an essential raw material. "Water Electrolysis has been around for many years and is considered to be a ZCE technology as well," said P. Peter Pascali, CEO and Chair of PyroGenesis. "The hydrogen generated from this process is generally referred to as "Green Hydrogen", however it is recognized to be expensive, require a lot of energy for its production, and uses rare earth materials. PyroGenesis' new technology is geared to combine the best of both worlds; it is expected to be cheaper than most existing hydrogen processes while at the same time producing ZCE hydrogen." Given today's results, PyroGenesis' plasma-based hydrogen production could become a solution/ alternative to the carbon-intensive hydrogen production technologies currently being used. If so, it could be instrumental in economically enabling the chemical industry to decarbonize production of chemicals such as ammonia or methanol.

07:50 EST Tilt Holdings announces partnership with Coda Signature - TILT Holdings announced it has partnered with Coda Signature to launch the brand in Massachusetts. Expected to be available in the state within the first quarter of 2023 and in Ohio soon after, Coda is the ninth brand to join TILT's wide ranging brand portfolio that celebrates BIPOC- and women-owned brands. "Coda is a brand that stands out for its award-winning products and experience with operations in one of the country's most mature recreational markets," said Gary Santo, TILT's chief executive officer. "With our award-winning kitchen and Coda's proven products, TILT is well-equipped to develop a new following for Coda's fan-favorite chocolate bars and Fruit Notes with consumers and patients in Massachusetts."

07:48 EST Unicycive Therapeutics completes enrollment of bioequivalence study for RENAZORB - Unicycive Therapeutics announced that it has completed the enrollment of subjects in the RENAZORB bioequivalence study. RENAZORB is an investigational phosphate binding agent utilizing proprietary nanoparticle technology that is being developed to treat hyperphosphatemia in CKD patients on dialysis. The study is a randomized, open-label, two-way crossover BE study to establish pharmacodynamic bioequivalence between RENAZORB and Fosrenol-the reference listed drug. Unicycive previously received confirmatory guidance from the U.S. Food and Drug Administration that this single BE study in healthy volunteers would satisfy the requirements and that no other clinical studies are required for a New Drug Application filing through the 505(b)(2) pathway. The study enrolled 40 subjects per treatment arm for 64 evaluable subjects. The study design, including the dose, primary endpoint, and sample size, was reviewed by, and aligned with the FDA before the initiation of the study. The primary endpoint of the study is LS mean change in urinary phosphate excretion from baseline to the evaluation period.

07:47 EST Tilray announces expansion of its CANACA cannabis brand portfolio - Tilray Brands announced the expansion of their CANACA cannabis brand portfolio. The brand's latest product release includes the launch of three new high-potency full-spectrum butane hash oil, BHO, infused products, along with expanded distribution of its current collection across Canada, for discerning cannabis enthusiasts, demanding boosted experiences.

07:46 EST Theriva Biologics reschedules conference call for Q3 results - Theriva Biologics announced that it plans to host a conference call on Friday, November 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update. The call was originally scheduled for Thursday, November 10, 2022, at 8:30 a.m. ET.

07:44 EST SportsTek Acquisition, Metavisio extend exclusivity period for discussions - SportsTek Acquisition Corp. announced that it has extended the exclusivity period under the non-binding letter of intent with Metavisio, a French company specializing in building, marketing, and selling laptops, whose securities are listed on Euronext Growth in Paris, with respect to a proposed business combination transaction. The Proposed Transaction is based on an enterprise value of Metavisio of USD 140 million to USD 160 million; however, such valuation is subject to due diligence by the Company of Metavisio. The exclusivity period for due diligence and the negotiation of a definitive agreement, as extended, will expire on December 9. 2022. A binding commitment with respect to the Proposed Transaction by the Company will only result from the execution of a definitive agreement and then only upon the terms and conditions set forth in the definitive agreement. There can be no assurance that the Company and Metavisio will enter into a definitive agreement with respect to the Proposed Transaction, or, if entered into, there is no certainty of the terms that will be contained in such definitive agreement.

07:42 EST Solid Bioscience expects cash, cash equivalents to fund operations into Q2 2024 - Solid had $142.2 million in cash, cash equivalents and available-for-sale securities as of September 30, 2022, compared to $207.8 million as of December 31, 2021. The company expects that its cash, cash equivalents and available-for-sale securities will enable it to fund its operations and capital expenditures into the second quarter of 2024, without giving effect to the acquisition of AavantiBio and $75 million private placement.

07:40 EST CorMedix expects cash to fund operations at least through 2023 - Total cash on hand and short-term investments as of September 30, 2022 was $59.0 million, excluding restricted cash of $0.2 million. The Company believes that, based on the Company's cash resources at September 30, 2022, it has sufficient resources to fund operations at least through 2023.

07:35 EST Six Flags amends pact with H Partners allowing boost to beneficial ownership - Six Flags Entertainment announced that the company and H Partners agreed to amend their existing Cooperation Agreement to permit H Partners to increase its beneficial ownership of Six Flags common stock to 19.9%, up from a cap of 14.9% in the original agreement. "H Partners has been a constructive and important partner to the company. We are pleased they continue to recognize the value potential of Six Flags and the progress management is making for our shareholders," said Ben Baldanza, Non-Executive Chairman of the Board. "We are excited about the company's strategy to deliver an exceptional guest experience and to drive sustainable, long-term earnings growth," said Arik Ruchim, a Partner at H Partners and director on the Six Flags Board. "We believe that meaningful change takes time to implement, and we are encouraged by the early signs of progress on this ambitious journey."

07:33 EST XP Inc. to purchase 5.5M shares from Itausa for $105M - XP Inc. announced that it has signed a share purchase agreement with Itausa S.A. Under this agreement, XP will purchase 5,500,000 outstanding Class A common shares from Itausa S.A., equivalent to approximately $105M, in the same conditions for which Itausa sold 10,000,000 Class A shares on November 9. XP should utilize its existing cash to fund this share repurchase and the shares should be held in treasury. This transaction is not part of the share repurchase program announced by XP on May 11.

07:31 EST Archer Aviation, United Airlines announce first airport to city center route - Archer Aviation (ACHR) and United Airlines (UAL) announced their first airport to city center route between United's hub at Newark Liberty International Airport, or EWR, and New York City. The Downtown Manhattan Heliport, located just above Battery Park on Pier 6, has been confirmed as the first planned takeoff and landing site as part of Archer's broader plan to launch an Urban Air Mobility, or UAM, network across the New York Metropolitan Area. The goal of Archer's electric air taxi network is to provide passengers with safe, quick, quiet and cost-effective transportation to and from EWR. Archer's proposed Manhattan to EWR route marks the first specific route that has been announced in the eVTOL industry. United's hub at EWR is ideally located to serve Manhattan and its surrounding boroughs, as well as communities in New Jersey. Archer estimates the journey from the Downtown Manhattan Heliport to EWR will take less than 10 minutes via its all-electric Midnight aircraft, a low noise, sustainable and safe alternative to helicopters. A similar journey by car can take upwards of an hour or more during rush hour traffic.

07:29 EST BeiGene announces Brukinsa approval in Brazil - BeiGene announced Brukinsa has been approved in Brazil for the treatment of adult patients with Waldenstrom's macroglobulinemia, or WM, and adult patients with relapsed/refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. Brukinsa was previously approved as a treatment in Brazil for adult patients with mantle cell lymphoma, or MCL, who have received at least one prior therapy. BeiGene is focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide.

07:27 EST Standard Lithium reports $124M cash on hand as of September 30 - "Q1 was an important quarter for Standard Lithium, in which we advanced our development strategy in meaningful ways - and have continued this momentum into the current quarter," said Robert Mintak, Chief Executive Officer and Director. "We achieved milestones, the most significant of which was awarding the Front-End Engineering and Design and Definitive Feasibility Study for our first commercial lithium plant. That work is successfully underway, with trade-off studies being completed, and the FEED and DFS for Phase 1A on schedule for delivery in the first half of 2023 and will be summarized in a NI 43-101 DFS report. We also added key personnel to the management team and to the workforce at our Arkansas facility, a team that I am proud to report now numbers 30 highly skilled operators, technicians, and engineers. We successfully commissioned a first-of-its-kind chloride-to-hydroxide conversion pilot plant in October. In November, we commenced a significant resource expansion program that includes re-drilling an existing production well into the deeper Smackover Formation at a location west of our South-West Arkansas Project. Additionally, we also received Notices of Allowance for Standard Lithium's first two U.S. patent applications." "The Company has had meaningful dialogue and hosted a number of site visits with groups over the past several months and we are evaluating potential strategic partnerships and supply agreements that will support the further development of our projects," concluded Mintak. "These initiatives, our continuing momentum toward key milestones, and our strong cash position will allow us to advance our commercial development strategy with confidence."

07:22 EST Finch Therapeutics expects cash to fund operations into 2Q24 - Finch's cash and cash equivalents as of September 30, 2022 were $85.3 million, compared to $133.5 million as of December 31, 2021. Finch believes its cash and cash equivalents on hand as of September 30, 2022, together with anticipated cash inflows from executed subleases for one of the Company's office and lab facilities, will fund its operations into Q2 2024.

07:19 EST Humacyte expects cash to fund operations through 2024 - The Company reported cash, cash equivalents and short-term investments of $171.7 million as of September 30, 2022, compared to $225.5 million as of December 31, 2021. The $53.8 million net use of cash, cash equivalents and short-term investments for the first nine months of 2022 resulted from spending related to net operating activities for the period, including clinical and earlier-stage research and development programs, and preparation for the Company's anticipated commercial launch. The Company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through 2024, past the Company's current expected timeline for potential approval of the HAV in vascular trauma.

07:15 EST Jounce Therapeutics expects cash to fund operating expenses into 1Q24 - Based on its current operating and development plans and cost containment efforts, Jounce is reiterating its financial guidance for 2022. Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be at the lower end of the range of $115.0 million to $130.0 million. Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements into the first quarter of 2024.

07:14 EST Larimar Therapeutics sees cash runway into 2H24 - As of September 30, 2022, the Company had cash and marketable securities totaling $124.7 million which provides projected cash runway into the second half of 2024.

07:12 EST Aravive expects cash, cash equivalents to fund operations into Q4 of 2023 - As of September 30, 2022, cash and cash equivalents were $27.9 million, compared to $46.8 million as of June 30, 2022 and $59.4 million as of December 31, 2021. During October 2022, the Company received a $6 million milestone payment from the Company's licensee, 3D Medicines, and raised approximately $41.5 million in gross proceeds from a private placement offering. The Company believes that its existing cash and cash equivalents will be sufficient to sustain operations into the fourth quarter of 2023.

07:11 EST Passage Bio to reduce workforce by 23%, focus on Imagine-1, upliFT-D programs - The company will decrease operating expenses by reducing the workforce by approximately 23 percent and prioritizing research and development investments. Moving forward, the company will focus on advancing its Imagine-1 and upliFT-D clinical programs for GM1 gangliosidosis and frontotemporal dementia, respectively. The company will stop further clinical development of PBKR03 for Krabbe disease and explore strategic alternatives to advance this program, as well as its program for metachromatic leukodystrophy, PBML04. The company will also prioritize advancing its programs for amyotrophic lateral sclerosis and Huntington's disease through its ongoing collaboration with the University of Pennsylvania's Gene Therapy Program.

07:09 EST EQRx expecst cash to fund operations into 2028 - Cash, cash equivalents and short-term investments totaled $1.5B at September 30, 2022. EQRx expects to maintain sufficient capital resources to fund anticipated operations into 2028, beyond its previous guidance of 2025.

07:07 EST BioLineRx: FDA accepts for review NDA for APHEXDA - BioLineRx announced that the U.S. FDA has accepted for review and filed the company's New Drug Application for APHEXDA in stem cell mobilization for autologous transplantation in multiple myeloma patients. The FDA has assigned the NDA a Prescription Drug User Fee Act target action date of September 9, 2023.

07:06 EST Target debuts new larger-format store - Target revealed the next evolution of its new store strategy and store design created to better serve its guests and team members and drive continued growth. Target's new larger-format stores optimize additional space and new design elements and at nearly 150,000 square feet, the locations are more than 20,000 square feet larger than the chain average. While the retailer will continue to open stores of all sizes, it will focus on this larger footprint in the next few years. Target also will bring its reimagined store design - which features a more open layout and localized elements to inspire and serve its guests - to future remodels as well as new stores across its chain. The retailer recently debuted the new store design and larger store format in a new location outside Houston. Starting in 2023, more than half of Target's approximately 200 full store remodels and almost all the retailer's approximately 30 new stores will include elements of the new design. Beginning in 2024, all of Target's remodels and new stores will feature the majority of the reimagined store design elements.

07:02 EST Werewolf Therapeutics expects cash to fund operations through 2Q24 - As of September 30, 2022, cash and cash equivalents decreased to $140.5 million, compared to $157.5 million as of December 31, 2021. Based on updated forecasting, the Company has extended its runway to project that its existing cash and cash equivalents, together with anticipated collaboration revenue and access to the term loan agreement with Pacific Western Bank, will be sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2024.

06:55 EST Lazard reports preliminary AUM $204.6B as of October 31 - The month's AUM included market appreciation of $8B, net outflows of $1.8B, and foreign exchange appreciation of $0.6B.

06:46 EST US Foods announces $500M share repurchase program - The repurchase authorization does not have an expiration date.

06:45 EST Hut 8 Mining mines 982 Bitcoin in Q3 - The company mined 982 Bitcoin in Q3, an 8.5% increase compared to Q3 2021 due to an increase in hashrate from the expansion of the company fleet of miners and mining activities. Hut 8's computing operations generated $4.4M of revenue in the quarter, the majority of which is monthly recurring revenue. The company installed an aggregate of 2,205 new MicroBT M30S, M30S+, M30S++ and M31S+ miners at its three mining sites during Q3. The installation of these miners brought Hut 8's operating capacity to 3.07 EH/s as of September 30, an increase of 10% in hashrate compared to June 30. "Our conservative approach to managing our balance sheet continues to be paramount for us at Hut 8," said Shane Downey, CFO of Hut 8. "Notably, we improved our mining capacity by 10% while reducing the average cost to mine each Bitcoin by 29%, when compared to the second quarter of 2022. We remain steadfastly committed to effectively managing capital in today's challenging environment and believe we are well positioned to deliver shareholder value in 2023 and beyond."

06:44 EST Outbrain raises 2022 adjusted EBITDA view to at least $23.2M from $18M - Raises FY22 Ex-TAC gross profit view to at least $232.5M from at least $228M.

06:29 EST Sono Motors partners with Bosch for Europe-wide car repair network - Sono Motors and German company Bosch have agreed to cooperate on a joint Europe-wide network of car repair shops. Owners of the Sion, Sono Motor's solar electric vehicle, will be able to use all services offered by participating car repair shops, including repair, servicing, maintenance, and warranty services. The overall 50 qualified Bosch Car Services to be trained in the launch phase will be distributed throughout Germany in such a way that both major cities and rural areas will be covered. Additional qualified service centers will be added in the subsequent rollout to create a comprehensive service network available in many European countries. The staff at Bosch partner workshops will receive comprehensive prior training from Sono Motors after which they will be authorized to perform repairs on high-voltage, photovoltaic, and safety systems with the assistance of, if necessary, Sono Motors Technical Field Service. The cooperation between Sono Motors and Bosch includes comprehensive repair, service, and proactive service work. As an accompanying measure, Sono Motors plans to provide tutorials for certain DIY maintenance on its website.

06:15 EST Triple Flag to acquire Maverix Metals for $3.92 per share, sees accretion - Triple Flag (TFPM) and Maverix Metals (MMX) announced that they have entered into a definitive agreement in which Triple Flag will acquire all of the issued and outstanding common shares of Maverix pursuant to a plan of arrangement, positioning Triple Flag as the emerging senior streaming and royalty company. This combination is expected to be accretive on a NAV-per-share and cash-flow-per-share basis. Pursuant to the transaction, Maverix shareholders may elect to receive either $3.92 in cash or 0.360 of a Triple Flag share per Maverix share held, representing share consideration of $3.92 per Maverix share based on the closing price of Triple Flag shares on November 9 of $10.89. The shareholder election will be subject to pro-ration such that the cash consideration will not exceed 15% of the total consideration and the share consideration will not exceed 85% of the total consideration. Maverix shareholders who do not elect to receive either Triple Flag shares or cash will be deemed to elect default consideration of 0.360 Triple Flag shares per Maverix share. The exchange ratio implies a premium of 10% based on the closing share prices of Triple Flag and Maverix on the New York Stock Exchange on November 9 and a premium of 22% based on the 10-day volume-weighted average share prices of Triple Flag and Maverix on the NYSE as of November 9. The purchase price implies a total equity value for Maverix of $606M on a fully diluted basis. Upon completion of the Transaction, existing Triple Flag and Maverix shareholders would own approximately 77% and 23% of the combined company, respectively, on a fully diluted basis. Triple Flag shareholder Elliott Investment Management L.P. and Maverix shareholders Newmont Corporation, Pan American Silver Corp. and Kinross Gold Corporation are all supportive of the combination. The combined company will continue as Triple Flag Precious Metals headquartered in Toronto, Ontario, and will be led by Shaun Usmar as CEO. Following the completion of the transaction, it is expected that Geoff Burns, founder and chair of Maverix, and another nominee of Maverix will join the Triple Flag board of directors. The combined company will continue to pay an annualized dividend of 20c per Triple Flag share, resulting in an effective dividend increase of over 40% for Maverix shareholders pro forma, based on the exchange ratio. Under the terms of the agreement, the transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act, and will require the approval of at least 66 2/3% of the votes cast by the shareholders of Maverix at a special meeting and if required, minority shareholder approval in accordance with Multilateral Instrument 61-101. Newmont Corporation (NEM) and Pan American Silver (PAAS), together with all of the officers and directors of Maverix, collectively control approximately 57% of the common shares of Maverix on a fully diluted basis and have entered into voting and support agreements pursuant to which they have agreed to vote their shares in favor of the transaction. As the Triple Flag shares to be issued to the shareholders of Maverix in the Transaction will exceed 25% of the issued and outstanding common shares of Triple Flag, Triple Flag shareholder approval of the transaction is required under Section 611(c) of the rules of the TSX. Triple Flag is relying on the exemption in Section 604(d) of the rules of the TSX, whereby instead of holding a shareholder meeting, Triple Flag has obtained the written consent for the Transaction of shareholders of Triple Flag holding greater than 50% of the issued and outstanding common shares of Triple Flag. Entities controlled by Elliott Investment Management L.P., which control approximately 83% of the issued and outstanding common shares of Triple Flag, have entered into voting and support agreements pursuant to which they have provided written consent to the transaction, and have agreed, if required, to vote their shares in favor of the Transaction at a Triple Flag shareholder meeting. Each of the officers and directors of Triple Flag have also entered into voting and support agreements, pursuant to which they have agreed to vote their shares in favor of the Transaction in the event of a Triple Flag shareholder meeting. Completion of the Transaction is also subject to regulatory and court approvals and other customary closing conditions. The agreement includes customary provisions, including non-solicitation by Maverix of alternative transactions, a right of Triple Flag to match superior proposals and an approximately $24M termination fee, payable under certain circumstances. Complete details of the transaction will be included in a management information circular to be delivered to Maverix shareholders in the coming weeks. Subject to receiving requisite court approval, the special meeting of shareholders of Maverix is expected to be held in early January 2023 and the transaction is also expected to close in January 2023. In connection with and subject to closing the Transaction, it is expected that the common shares of Maverix will be delisted from the TSX and the NYSE American and that Maverix will cease to be a reporting issuer under Canadian and U.S. securities laws.

06:09 EST National Vision reports Q3 comparable store sales growth (8.0%) - Adjusted comparable store sales growth was (8.1%).

05:43 EST Royal Caribbean opens $125M cruise terminal in Galveston with Allure of the Seas - Royal Caribbean's new $125M cruise terminal in Galveston, Texas, opened its doors and welcomed the Lone Star State's largest cruise ship, Allure of the Seas. The cruise line held a ribbon cutting ceremony at the Port of Galveston to mark the facility's opening and the Texas debut of its revolutionary Oasis Class.

05:28 EST Elbit Systems subsidiary awarded $19M follow-on contract from British Army - Elbit Systems announced that its subsidiary Elbit Systems was awarded a follow-on contract $19M valued at approximately $19M to supply Night Vision Goggles, or NVG, and through-life support to the British Army. The contract will be executed over a 18-month period. Under the contract, Elbit Systems UK will supply the lightweight micro binocular XACT nv33 NVGs in a helmet-mounted configuration. XACT nv33 NVG are designed to enable troops to operate effectively in low-light conditions at a tactical level, maximizing their mission efficiency in both dismounted and mounted roles. Products from the XACT family are already in operational use with a number of NATO members including the Netherlands and Germany.

05:19 EST Evaxion Biotech intends to further increase focus on EVX-01, EVX-02/03 assets - Evaxion Biotech announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The company further plans preclinical partnering of its early-stage programs under its infectious disease platforms. As previously announced by the company, the EVX-01 program recently started to enroll patients in the global Phase IIb trial in metastatic melanoma. At the same time, the Phase I/IIa trial of the DNA-based EVX-02 is progressing as planned, with data readout currently expected by mid-2023. The next-generation DNA vaccine, EVX-03, builds on EVX-02 and holds the potential for even stronger efficacy due to an integrated mechanism that boosts the immune system. The company plans to submit a regulatory filing of EVX-03, following EVX-02 data, which may allow Evaxion to advance EVX-03 faster to clinical proof of concept. "I am deeply impressed by the AI platforms and the quality of the innovative programs that Evaxion has developed. The Company holds several first-in-class assets within oncology and infectious diseases. In the current biotech market, however, we fully acknowledge the increasing need to center our activities. Consequently, our resources will be channeled into our leading clinical assets within personalized cancer immunotherapy," states Per Norlen, the company's new CEO. Norlen continues: "Our primary focus will be on our Phase IIb program for EVX-01 and our Phase I/IIa program for EVX-02/03. Regarding our early programs for infectious diseases, such as our Staphylococcus aureus vaccine, we aim to develop these in partnerships rather than bringing them into clinical development ourselves."